potential target in the treatment of pain and inflammatory and metabolic diseases. We have discovered a series of potent GPR35 agonists based on a coumarin scaffold and found that the introduction of a 1H-tetrazol-5-yl group significantly increased their potency. We designed and synthesized a new series of N-[2-(1H-tetrazol-5-yl)phenyl]benzamide derivatives through a two-step synthetic approach, and characterized
G蛋白偶联受体35(GPR35)已成为治疗疼痛,炎性和代谢性疾病的潜在靶标。我们已经发现了一系列基于
香豆素骨架的强效GPR35激动剂,并发现引入1 H-
四唑-5-基大大提高了它们的效价。我们通过两步合成方法设计和合成了一系列新的N- [2-(1 H-
四唑-5-基)苯基]苯甲酰胺衍
生物,并使用动态质量重新分配(
DMR)表征了它们对GPR35的激动活性。分析。N-(5-
溴-2-(1 H-
四唑-5-基)苯基)-4-
甲氧基苯甲酰胺(56)和N-(5-
溴-2-(1 H-
四唑-5-基)苯基)-2-
氟-4-
甲氧基苯甲酰胺(63)显示出最高的激动剂激动剂GPR35,
EC 50分别为0.059μM和0.041μM 。计算了所选化合物的理化性质,以评估其药物相似性,表明化合物56和63具有良好的药物相似性能。一起,Ñ - [2-(
1H-四唑-5-基)苯基]苯甲酰胺衍
生物是潜在地用于开发有效的GPR35激动剂大候选。